Gonorrhoea themed issue

Ison, Catherine; Hughes, Gwenda

doi:10.1136/sti.2010.046821

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since cephalosporins have lower efficacy in the treatment of pharyngeal compared with genital gonorrhoea, ciprofloxacin was recommended to treat pharyngeal infection if the isolate is found susceptible on laboratory testing. 10,25, 26 After treatment, a test of cure of pharyngeal infection is recommended, as all treatments are less effective at eradicating pharyngeal infection. 6…”

Section: Discussionmentioning

confidence: 99%

“…Current guidelines from the World Health Organization (WHO), US CDC and UK/Europe recommend that patients with uncomplicated gonococcal infections of the cervix, urethra or rectum should be treated with ceftriaxone 250–1000 mg intramuscularly as the first choice, and cefixime 400 mg tablet, another single dose cephalosporin regimen or spectinomycin 2 g if ceftriaxone is contraindicated or unavailable. 4,8–10 Ceftriaxone 125 mg is recommended to treat gonococcal infections acquired in Hawaii, California, Asia or other areas where an increased prevalence of fluoroquinolone resistance exists, and other third-generation cephalosporins can be considered based on sensitivity test results. 1 WHO suggested the standard dosage of ceftriaxone for uncomplicated gonorrhoea is 125 mg, but later research has reported this may lead to the development of antimicrobial resistance in N. gonorrhoeae (WHO, 2001).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials

Bai

Bao

et al. 2012

Int J STD AIDS

View full text Add to dashboard Cite

We conducted a systematic review and meta-analysis of ceftriaxone for treatment of uncomplicated gonorrhoea compared with four other antibiotics. Thirteen randomized controlled trials (RCTs) totalling treatment of 2557 patients with uncomplicated gonorrhoea were included. Statistically significant differences were observed in side-effects, which were increased after ceftriaxone 250 mg versus cefotaxime 500 mg (odds ratio [OR] 1.87; 95% confidence interval [CI] 1.14-3.08). Cure rates of ceftriaxone 250 mg were significantly better than cefixime 400 mg (OR 1.77; 95% CI 1.11-2.80) as was ceftriaxone 125 mg versus spectinomycin 2 g (OR 3.44; 95% CI 1.08-10.90). There was no statistically significant difference between ceftriaxone 250 mg and cefixime 800 mg in cure rates (OR 1.39; 95% CI 0.92-2.10) or adverse effects (OR 1.29, 95% CI 0.58-2.84) for treating uncomplicated gonorrhoea. The cure rate after ceftriaxone 250 mg was not significantly different from that after spectinomycin 2 g (OR 1.96; 95% CI 1.00-3.87). In conclusion, this meta-analysis revealed that 250 mg ceftriaxone had a higher efficacy than 400 mg cefixime for uncomplicated gonorrhoea. Also, ceftriaxone 125 mg is a better choice than spectinomycin 2 g for patients with uncomplicated gonorrhoea, but ceftriaxone had higher side-effect rates than cefotaxime. In the current era further randomized controlled clinical trials of ceftriaxone for uncomplicated gonorrhoea are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials

Bai

Bao

et al. 2012

Int J STD AIDS

View full text Add to dashboard Cite

show abstract

“…In Western industrialised countries, gonorrhoea disproportionately affects black ethnic minorities and men who have sex with men (MSM)2 and controlling the spread of infection is probably best achieved through intervention measures targeting these populations 3. With the global emergence of gonococcal resistance to antimicrobials, primary prevention could become increasingly important for infection control 4 5…”

Section: Introductionmentioning

confidence: 99%